IACM-Bulletin du 04 Août 2020 IACM: Prolongation de la date limite de soumission des résumés pour la conférence virtuelle IACM 2020 sur les cannabinoïdes - Opportunités spéciales de parrainage Europe: Dans un premier temps, la Commission Européenne déclare que le chanvre industriel est un stupéfiant Science/Homme: Le cannabis efficace pour le traitement de la migraine Argentine: Le pays autorise la vente de cannabis en pharmacie et la culture à domicile Science/Homme: Selon une étude, le CBD est un traitement sûr pour les troubles liés à la consommation de cannabis En bref Un [...]
Lire la suiteIACM-Bulletin du 24 Août 2020 Thaïlande: Les patients peuvent cultiver leur propre cannabis à des fins médicales Science/Homme: Le THC peut être utile dans le traitement du trouble de stress post-traumatique Science/Homme: La consommation de cannabis est associée à une charge virale réduite chez les personnes séropositives qui consomment de la cocaïne Science/Homme: Dans une étude clinique, le CBD était efficace dans le traitement des troubles liés à l'usage du cannabis Science/Homme: La consommation de cannabis associée à une réduction des décès à l'hôpital dus à l'insuffisance cardiaque En bref Un coup [...]
Lire la suiteIACM-Bulletin du 07 Septembre 2020 Israël: La réduction des prix du cannabis médical et le CBD n'est plus un stupéfiant Science/Homme: La consommation fréquente de cannabis réduit la consommation d'opioïdes Science/Homme: La consommation de cannabis est associée à une réduction du risque de diabète chez les personnes atteintes d'hépatite C Science/Homme: La consommation de cannabis réduit l'hospitalisation des patients drépanocytaires En bref Un coup d'œil sur le passé Israël: La réduction des prix du cannabis médical et le CBD n'est plus un stupéfiant Le ministre de la Santé Yuli Edelstein et son adjoint [...]
Lire la suiteWhat Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ? Robin M. Murray, Alessandra Paparelli, Paul D. Morrison, Arianna Marconi, and Marta Di Forti American Journal of Medical Genetics, Part B, 2013, 162B, 661–670. Doi : 10.1002/ajmg.b.32177 When drug-induced psychoses were first identified in the mid- 20th century, schizophrenia was considered a discrete disease with a likely genetic cause. Consequently, drug-induced psychoses were not considered central to understanding schizophrenia as they were thought to be phenocopies rather than examples of the illness secondary to a particular known cause. However, now that we know that schizophrenia is a clinical syndrome with [...]
Lire la suiteCannabinoids : Extraction Methods, Analysis and Physicochemical Characterization Cristina Lujan RAMIREZ, Maria Alejandra FANOVICH, Maria Sandra CHURIO. Studies in Natural Products Chemistry, Chapter 4, 2019, Volume 61, 143-173 (1-44). Doi : 10.1016/B978-0-444-64183-0.00004-X ABSTRACT : A new paradigm has been established in the application of cannabinoids in the last decade. The growing accessibility to different types of Cannabis products and the rise in concern about their health benefits have provoked a rapid expansion of the research interests in phytocannabinoids with promising pharmacological properties. The characterization of the diverse chemotypes of Cannabis sativa, the elucidation of their various structures, and quantification of cannabinoids in the complex [...]
Lire la suiteThe association between cannabis use and mood disorders : A longitudinal study Daniel Feingold, Mark Weiser, Jürgen Rehme, Shaul Lev-Ran Journal of Affective Disorders, 2015, 172, 211–218. doi : 10.1016/j.jad.2014.10.006 a b s t r a c t Background : The association between cannabis use and mood disorders is well documented, yet evidence regarding causality is conflicting. This study explored the association between cannabis use, major depressive disorder (MDD) and bipolar disorder (BPD) in a 3-year prospective study. Methods : Data was drawn from waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). MDD and BPD were controlled at baseline [...]
Lire la suiteCancer, Cannabis, and the Search for Relief Marcin Chwistek JNCCN—Journal of the National Comprehensive Cancer Network, 2019, Volume 17, Issue 9, 1142-1144. doi : 10.6004/jnccn.2019.7347 “How about medical marijuana?” is a common and often challenging question in oncology clinics today. It is easy to see why. Answering the question is fraught with clinical, legal, and administrative uncertainties. We all want to give patients the best advice, but not much about medical cannabis seems straightforward today. Whatever answer we provide can feel unsatisfactory to patients or ourselves. Answering clinical questions through high-quality research will take many years. And significant political power will be needed to [...]
Lire la suiteA low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers Johannes G. Ramaekers, Nadia Hutten, Natasha L. Mason, Patrick Dolder1, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding and Kim P.C. Kuypers Journal of Psychopharmacology, 2020, 1–8. doi : 10.1177/026988112094093 Abstract Background : Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim : The present [...]
Lire la suiteThe Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer Oliviero Marinelli, Maria Beatrice Morelli, Daniela Annibali, Cristina Aguzzi, Laura Zeppa, Sandra Tuyaerts, Consuelo Amantini, Frédéric Amant, Benedetta Ferretti, Federica Maggi, Giorgio Santoni, Massimo Nabissi International Journal of Molecular Sciences, 2020, 21, 5409 doi : 10.3390/ijms21155409 Abstract : Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with [...]
Lire la suiteFDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation Ralph Ellis Medscape, August 21, 2020 The US Food and Drug Administration has approved phase one clinical trials for a synthetic cannabinoid drug designed to treat acute respiratory distress syndrome (ARDS), a life-threatening lung condition which may occur in severe cases of the novel coronavirus, Forbes reported. ARDS can be triggered by over-creation of cytokines, proteins which tell the body to produce more inflammation, Forbes said. The drug going to clinical trials, ARDS-003, would “dampen the cytokine release" and prevent development of ARDS, Tetra Bio-Pharma company CEO and chief regulatory officer Guy Chamberland, MD, [...]
Lire la suite